Focusing on key groups will drive the greatest impact in health outcomes
Not quite specialty, not quite retail: Cost-effective access and support strategies for a growing, yet underserved, treatment market
Although companies are faced with constraints, regulations, and challenges in this space, the positives supersede the negatives.
The rationale behind transforming case management in healthcare.
Digital transformation initiatives are often complex endeavors that can significantly impact the way organizations operate.
Outlining five questions that should be considered when assessing if RWD is “fit for purpose” in pharma research—and ultimately clinical and pharmacy decision support
Faster approvals, more accurate and timely medicines monitoring—all enabled by harmonized, consistent and reliable data—will drive improved patient outcomes.
The advantages and challenges associated with structuring a patient assistance program as a non-profit foundation.
Questions to ask before transitioning into new technologies. By Yvonne Duckworth and Cory Perelman.
Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.
The importance of industry, as it moves forward, in focusing on patient-centered care and prioritizing patient needs across the supply chain.
Rob Truckenmiller, CEO of PharmaCord, talks about the company’s role in patient services, trends he sees shaping patient access to healthcare in the U.S., and a recent patient-centric merger.
How current frameworks influence coverage decisions and pricing negotiations.
Outlining the core functional skill sets of the most effective hub programs—all toward the goal of helping patients get on prescriptions as quickly as possible
Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.
How pharma’s retooling of its promotional efforts in the post-pandemic era impacts sizing and targeting, two crucial foundational pieces to successful commercialization
Following a decade of solid groundwork to modernize regulatory information management in life sciences, leading companies have now shifted their focus to how they might exploit this new digital landscape
By 2050, study estimates that cancer incidence and mortality rates will nearly triple in low-Human Development Index countries, highlighting an urgent need for enhanced global cancer prevention, early detection, and treatment strategies to address growing disparities.
How artificial intelligence is improving the patient experience
While this concern is causing ripples in the global supply chain, technological and regulatory advances can help address the issue
A comprehensive data and analytics strategy is now table stakes for pharmaceutical and life science organizations, writes Simon Andrews
Duplicate rebates have resulted in revenue leakage for manufacturers.
Pandemic preparedness and curbing PBMs among the pending legislation that will have to wait until after summer recess.
As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.
Ways to address limitations while also enhancing the decision-making process.
The clinical research industry must integrate feedback from patients and sites to eliminate unnecessary burden and accelerate enrollment in clinical trials
In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Questions to ask before transitioning into new technologies. By Yvonne Duckworth and Cory Perelman.
Observations from recent digital health events and a glimpse of what’s ahead—from Milan to Boca Raton
When delays and disruptions threaten not only product integrity but patient well-being, thorough risk assessment and mitigation are essential.